• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Identifying patients at risk: multi ‐centre comparison of HeartMate 3 and HeartWare left ventricular assist devices
ConclusionsHM3 patients have a significantly better survival and a lower incidence of ischaemic strokes and pump thrombosis than HVAD patients. This survival difference persisted after 2  years of implantation. Additional research using post-operative variables is warranted to identify which HVAD patients need an upgrade to HM3 or expedited transplantation.
Source: ESC Heart Failure - February 17, 2023 Category: Cardiology Authors: Lieke Numan, Daniel Zimpfer, Osnat Itzhaki Ben Zadok, Emmeke Aarts, Michiel Morshuis, Sabina P.W. Guenther, Julia Riebandt, Dominik Wiedemann, Faiz Z. Ramjankhan, Anne ‐Marie Oppelaar, Tuvia Ben‐Gal, Binyamin Ben‐Avraham, Folkert W. Asse Tags: Original Article Source Type: research

Complications of left ventricular assist devices causing high urgency status on waiting list: impact on outcome after heart transplantation
ConclusionsLeft ventricular assist device therapy can impair the outcome after HTx. However, the occurrence of LVAD complications may not impact on outcome after HTx. Thus, we cannot support the prioritization or discrimination of HTx candidates according to distinct mechanical circulatory support ‐associated complications. Future allocation strategies have to respect that device‐related complications may define urgency but do not impact on the outcome after HTx.
Source: ESC Heart Failure - March 29, 2021 Category: Cardiology Authors: Moritz Benjamin Immohr, Udo Boeken, Franziska Mueller, Emir Prashovikj, Michiel Morshuis, Charlotte B öttger, Hug Aubin, Jan Gummert, Payam Akhyari, Artur Lichtenberg, René Schramm Tags: Original Research Article Source Type: research

Propensity score ‐based analysis of long‐term outcome of patients on HeartWare and HeartMate 3 left ventricular assist device support
ConclusionsSurvival was not significantly different between both groups after PS matching, but was better for HM3, with a significantly lower incidence of haemorrhagic stroke and pump thrombosis for HM3. These results need to be interpreted carefully, because matching may have introduced greater imbalance on unmeasured covariates. A multicentre approach of carefully selected centres is recommended to enlarge the number of matched patients.
Source: ESC Heart Failure - February 26, 2021 Category: Cardiology Authors: Lieke Numan, Faiz Z. Ramjankhan, Daniel L. Oberski, Martinus I.F.J. Oerlemans, Emmeke Aarts, Monica Gianoli, Joris J. Van Der Heijden, Nicolaas De Jonge, Niels P. Van Der Kaaij, Christiaan L. Meuwese, Mostafa M. Mokhles, Anne ‐Marie Oppelaar, Tags: Original Research Article Source Type: research

Complications of left ventricular assist devices causing high urgency status on waiting list: impact on outcome after heart transplantation
ConclusionsLeft ventricular assist device therapy can impair the outcome after HTx. However, the occurrence of LVAD complications may not impact on outcome after HTx. Thus, we cannot support the prioritization or discrimination of HTx candidates according to distinct mechanical circulatory support ‐associated complications. Future allocation strategies have to respect that device‐related complications may define urgency but do not impact on the outcome after HTx.
Source: ESC Heart Failure - January 21, 2021 Category: Cardiology Authors: Moritz Benjamin Immohr, Udo Boeken, Franziska Mueller, Emir Prashovikj, Michiel Morshuis, Charlotte B öttger, Hug Aubin, Jan Gummert, Payam Akhyari, Artur Lichtenberg, René Schramm Tags: Original Research Article Source Type: research

Biventricular imaging markers to predict outcomes in non ‐compaction cardiomyopathy: a machine learning study
ConclusionsOur findings show the importance of biventricular assessment to detect the severity of this cardiomyopathy and to plan for early clinical intervention. In addition, this study shows that even patients with normal LV function and negative late gadolinium enhancement had MACE. ML is a promising tool for analysing a large set of parameters to stratify and predict prognosis in LVNC patients.
Source: ESC Heart Failure - June 29, 2020 Category: Cardiology Authors: Camila Rocon, Mahdi Tabassian, Marcelo Dantas Tavares de Melo, Jose Arimateia Araujo Filho, Cesar Jos é Grupi, Jose Rodrigues Parga Filho, Edimar Alcides Bocchi, Jan D'hooge, Vera Maria Cury Salemi Tags: Original Research Article Source Type: research